A Phase 3 interventional study of Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine in Meningococcal Immunisation and Healthy Volunteers, sponsored by Sanofi Pasteur, a Sanofi Company. Active, not recruiting at 27 sites in 4 countries. Open to participants aged 6 Years to 7 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the MEQ00073 study is to describe the immunogenicity and safety of a booster dose and persistence of a priming dose of MenACYW conjugate vaccine (MenQuadfi®) in adolescents who had been vaccinated approximately 10 years earlier as toddlers as part of the MET51 study and to describe the immunogenicity and safety of a second booster dose (as adolescents approximately 5 years after the first booster dose) and the persistence of a first booster dose of MenACYW in adolescents who had been primed with MenACYW conjugate vaccine as toddlers as part of the MET51 study and had received a first booster dose as children approximately 5 years after the priming dose.
The duration of each participant's participation will be approximately 5.5 years
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
First submitted after Sanofi Pasteur became part of Sanofi.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a first booster dose of MenACYW conjugate vaccine at Day 1 and a second booster dose at year 5 of study MEQ00073
Biological: Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine
Participants will receive a single booster dose of MenACYW conjugate vaccine at year 5 of study MEQ00073
Biological: Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine
Liquid solution for injection Intramuscular
Also known as: MenACYW conjugate vaccine MenQuadfi®
Group 1: Percentage of Participants With Sufficiency of Serum Bactericidal Assay Using Human Complement (hSBA) Vaccine Seroresponse at 30 Days Post Booster Dose
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse for serogroups A, C, W, and Y is defined as: percentage of participants with a pre-vaccination titer \< 1:8, who had achieved a post-vaccination titer \>= 1:16 or participants with a pre-vaccination titer \>= 1:8, who had achieved a post-vaccination titer at least 4-fold greater than the pre-vaccination titer. The seroresponse sufficiency was demonstrated if the lower limit of 1-sided 97.5% confidence interval (CI) is \> 75%.
Time frame: Baseline (Day 1) and 30 days after the MenACYW conjugate vaccine 5-year booster dose
Antibody Persistence of Meningococcal (Groups 1 and 2): Percentage of Participants Achieving Titer (Seroprotection) >=1:8 hSBA and Serum Bactericidal Assay Using Baby Rabbit Complement (rSBA) Titer >=1:8 Approximately 5 Years After the Primary Vaccination
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA and the rSBA and the results were expressed as vaccine seroprotection. Seroprotection rate is defined as percentage of participants with hSBA titer and rSBA titer \>=1.8 who received MenACYW conjugate vaccine 5 years earlier. Antibody persistence of meningococcal serogroups A, C, W, and Y in children at 5 years (Groups 1 and 2).
Time frame: At Day 1 (approximately 5 year after the administration of a priming dose as toddlers in study MET51)
Group 1: Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA and the rSBA and the results were expressed as geometric mean titers.
Time frame: Baseline (Day 1) and Day 31 after the administration of a 5-year booster dose
Group 2: Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA and the rSBA and the results were expressed as geometric mean titers.
Time frame: From Baseline (Day 1) until end of the study (approximately 5.5 years)
Group 1: Percentage of Participants With hSBA Titer >= 1:4 and >= 1:8
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:16 for participants with pre-vaccination hSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination hSBA titer \>= 1:8.
Time frame: Baseline (Day 1) and Day 31 after the administration of a 5-year booster dose
Group 2: Percentage of Participants With hSBA Titer >= 1:4 and >= 1:8
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:16 for participants with pre-vaccination hSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination hSBA titer \>= 1:8.
Time frame: From Baseline (Day 1) until end of the study (approximately 5.5 years)
Group 1: Percentage of Participants With rSBA Titer >= 1:8 and >= 1:128
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:32 for participants with pre-vaccination rSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination rSBA titer \>= 1:8.
Time frame: Baseline (Day 1) and Day 31 after the administration of a 5-year booster dose
Group 2: Percentage of Participants With rSBA Titer >= 1:8 and >= 1:128
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:32 for participants with pre-vaccination rSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination rSBA titer \>= 1:8.
Time frame: From Baseline (Day 1) until end of the study (approximately 5.5 years)
Group 1: Percentage of Participants With hSBA Titer >=4-Fold Rise From Pre-Vaccination to Post-Vaccination
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:16 for participants with pre-vaccination hSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination hSBA titer \>= 1:8.
Time frame: Baseline (Day 1) and Day 31 after the administration of a 5-year booster dose
Group 2: Percentage of Participants With hSBA Titer >=4-Fold Rise From Pre-Vaccination to Post-Vaccination
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:16 for participants with pre-vaccination hSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination hSBA titer \>= 1:8.
Time frame: From Baseline (Day 1) until end of the study (approximately 5.5 years)
Group 1: Percentage of Participants With rSBA Titer >=4-Fold Rise From Pre-Vaccination to Post-Vaccination
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:32 for participants with pre-vaccination rSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination rSBA titer \>= 1:8.
Time frame: Baseline (Day 1) and Day 31 after the administration of a 5-year booster dose
Group 2: Percentage of Participants With rSBA Titer >=4-Fold Rise From Pre-Vaccination to Post-Vaccination
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:32 for participants with pre-vaccination rSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination rSBA titer \>= 1:8.
Time frame: From Baseline (Day 1) until end of the study (approximately 5.5 years)
Group 1: Percentage of Participants With >=0.01 International Units (IU)/mL and >=0.1 IU/mL Anti-Tetanus Antibody Concentration
Anti-tetanus antibodies were measured by diphtheria, tetanus, pertussis multiplexed electrochemiluminescent (DTP-ECL) assay, a multiplexed serological assay that allowed for the simultaneous quantification of human antibodies to 6 specific antigens including diphtheria toxoid, tetanus toxoid, and 4 pertussis antigens: pertussis toxin, filamentous hemagglutinin, fimbriae and pertactin. The captured antibodies were then detected using a sulfotag-conjugated anti-human immunoglobulin (Ig)G conjugate.
Time frame: Baseline (Day 1) and Day 31 after the administration of a 5-year booster dose
Group 2: Percentage of Participants With >=0.01 International Units (IU)/mL and >=0.1 IU/mL Anti-Tetanus Antibody Concentration
Anti-tetanus antibodies were measured by diphtheria, tetanus, pertussis multiplexed electrochemiluminescent (DTP-ECL) assay, a multiplexed serological assay that allowed for the simultaneous quantification of human antibodies to 6 specific antigens including diphtheria toxoid, tetanus toxoid, and 4 pertussis antigens: pertussis toxin, filamentous hemagglutinin, fimbriae and pertactin. The captured antibodies were then detected using a sulfotag-conjugated anti-human immunoglobulin (Ig)G conjugate.
Time frame: From Baseline (Day 1) until end of the study (approximately 5.5 years)
Group 1: Geometric Mean Concentrations of Anti-Tetanus Antibody Concentration
Anti-tetanus antibodies were measured by DTP-ECL assay, a multiplexed serological assay that allowed for the simultaneous quantification of human antibodies to 6 specific antigens including diphtheria toxoid, tetanus toxoid, and 4 pertussis antigens: pertussis toxin, filamentous haemagglutinin, fimbriae and pertactin. The captured antibodies were then detected using a sulfotag-conjugated anti-human Ig G conjugate.
Time frame: Baseline (Day 1) and Day 31 after the administration of a 5-year booster dose
Group 2: Geometric Mean Concentrations of Anti-Tetanus Antibody Concentration
Anti-tetanus antibodies were measured by DTP-ECL assay, a multiplexed serological assay that allowed for the simultaneous quantification of human antibodies to 6 specific antigens including diphtheria toxoid, tetanus toxoid, and 4 pertussis antigens: pertussis toxin, filamentous haemagglutinin, fimbriae and pertactin. The captured antibodies were then detected using a sulfotag-conjugated anti-human Ig G conjugate.
Time frame: From Baseline (Day 1) until end of the study (approximately 5.5 years)
Group 1: Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. An unsolicited AE is an observed AE that does not fulfill the conditions of solicited reactions (i.e.pre-listed in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination).
Time frame: Within 30 minutes after vaccination
Group 1: Number of Participants With Solicited Injection Site Reactions and Systemic Reactions
All noxious and unintended responses to a study vaccine related to any dose was considered adverse reactions (AR). A solicited reaction is an "expected" AR (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRB. An injection/administration site reaction is an AR at and around the injection/administration site. Injection/administration site reactions are commonly inflammatory reactions. They were considered to be related to the study vaccine administered. Systemic reactions were all ARs that were not injection or administration site reactions and included systemic manifestations such as headache, fever, as well as localized or topical manifestations that are not associated with the vaccination or administration site.
Time frame: 7 days after vaccination
Group 1: Number of Participants With Unsolicited AEs
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. An unsolicited AE is an observed AE that does not fulfill the conditions of solicited reactions (i.e. pre-listed in the CRB in terms of diagnosis and/or onset window post-vaccination). Unsolicited AEs included both serious and non-serious unsolicited AEs.
Time frame: Within 30 days after vaccination
Group 1: Number of Participants With Serious AEs (SAEs) and Adverse Event of Special Interest (AESI)
A SAEs is defined as any untoward medical occurrence, at any dose that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, or other important medical event. An AESI (serious or non-serious) is defined as one of scientific and medical concern specific to the Sponsor's study vaccination or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate.
Time frame: From the first study vaccine administration up to primary completion date of 09 March 2023, approximately 28 weeks
The study was conducted at 26 centers in 4 countries from 23 August 2022 to 06 February 2023.
| Milestone | MenACYW: Group 1 | MenACYW: Group 2 |
|---|---|---|
| Started | 93 | 116 |
| Completed | 92 | 116 |
| Not completed | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse for serogroups A, C, W, and Y is defined as: percentage of participants with a pre-vaccination titer \< 1:8, who had achieved a post-vaccination titer \>= 1:16 or participants with a pre-vaccination titer \>= 1:8, who had achieved a post-vaccination titer at least 4-fold greater than the pre-vaccination titer. The seroresponse sufficiency was demonstrated if the lower limit of 1-sided 97.5% confidence interval (CI) is \> 75%.
| percentage of participants | MenACYW: Group 1 |
|---|---|
| Serogroup A | 93.2 (85.7 to NA) |
| Serogroup C | 97.7 (92.0 to NA) |
| Serogroup W | 98.9 (93.8 to NA) |
| Serogroup Y | 98.9 (93.8 to NA) |
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA and the rSBA and the results were expressed as vaccine seroprotection. Seroprotection rate is defined as percentage of participants with hSBA titer and rSBA titer \>=1.8 who received MenACYW conjugate vaccine 5 years earlier. Antibody persistence of meningococcal serogroups A, C, W, and Y in children at 5 years (Groups 1 and 2).
| percentage of participants | MenACYW: Group 1 | MenACYW: Group 2 |
|---|---|---|
| hSBA titer >=1.8, Serogroup A | 78.3 (68.4 to 86.2) | 74.1 (65.2 to 81.8) |
| hSBA titer >=1.8, Serogroup C | 83.7 (74.5 to 90.6) | 86.2 (78.6 to 91.9) |
| hSBA titer >=1.8, Serogroup W | 84.8 (75.8 to 91.4) | 84.5 (76.6 to 90.5) |
| hSBA titer >=1.8, Serogroup Y | 71.7 (61.4 to 80.6) | 66.4 (57.0 to 74.9) |
| rSBA titer >=1.8, Serogroup A | 71.7 (61.4 to 80.6) | 61.7 (52.2 to 70.6) |
| rSBA titer >=1.8, Serogroup C | 59.8 (49.0 to 69.9) | 58.6 (49.1 to 67.7) |
| rSBA titer >=1.8, Serogroup W | 57.6 (46.9 to 67.9) | 58.0 (48.3 to 67.3) |
| rSBA titer >=1.8, Serogroup Y | 62.9 (52.0 to 72.9) | 60.6 (50.7 to 69.8) |
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA and the rSBA and the results were expressed as geometric mean titers.
| titer | MenACYW: Group 1 |
|---|---|
| Day 1: hSBA, Serogroup A | 17.2 (12.6 to 23.3) |
| Day 31: hSBA, Serogroup A | 1143 (820 to 1594) |
| Day 1: hSBA, Serogroup C | 36.9 (25.7 to 52.9) |
| Day 31: hSBA, Serogroup C | 8933 (6252 to 12764) |
| Day 1: hSBA, Serogroup Y | 14.6 (10.8 to 19.7) |
| Day 31: hSBA, Serogroup Y | 3727 (2908 to 4776) |
| Day 1: hSBA, Serogroup W | 29.3 (21.7 to 39.7) |
| Day 31: hSBA, Serogroup W | 8656 (6393 to 11721) |
| Day 1: rSBA, Serogroup A | 150 (81.7 to 275) |
| Day 31: rSBA, Serogroup A | 8454 (6869 to 10405) |
| Day 1: rSBA, Serogroup C | 31.5 (18.8 to 52.8) |
| Day 31: rSBA, Serogroup C | 20427 (14379 to 29018) |
| Day 1: rSBA, Serogroup Y | 64.5 (35.0 to 119) |
| Day 31: rSBA, Serogroup Y | 7814 (6111 to 9991) |
| Day 1: rSBA, Serogroup W | 49.7 (26.6 to 93.0) |
| Day 31: rSBA, Serogroup W | 23354 (17251 to 31615) |
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA and the rSBA and the results were expressed as geometric mean titers.
Results for this outcome have not been posted.
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:16 for participants with pre-vaccination hSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination hSBA titer \>= 1:8.
| percentage of participants | MenACYW: Group 1 |
|---|---|
| Day 1: hSBA >=1:4 titer, Serogroup A | 93.2 (85.7 to 97.5) |
| Day 31: hSBA >=1:4 titer, Serogroup A | 100 (95.9 to 100) |
| Day 1: hSBA >=1:8 titer, Serogroup A | 78.4 (68.4 to 86.5) |
| Day 31: hSBA >=1:8 titer, Serogroup A | 98.9 (93.8 to 100) |
| Day 1: hSBA >=1:4 titer, Serogroup C | 86.4 (77.4 to 92.8) |
| Day 31: hSBA >=1:4 titer, Serogroup C | 97.7 (92.0 to 99.7) |
| Day 1: hSBA >=1:8 titer, Serogroup C | 84.1 (74.8 to 91.0) |
| Day 31: hSBA >=1:8 titer, Serogroup C | 97.7 (92.0 to 99.7) |
| Day 1: hSBA >=1:4 titer, Serogroup Y | 78.4 (68.4 to 86.5) |
| Day 31: hSBA >=1:4 titer, Serogroup Y | 100 (95.9 to 100) |
| Day 1: hSBA >=1:8 titer, Serogroup Y | 73.9 (63.4 to 82.7) |
| Day 31: hSBA >=1:8 titer, Serogroup Y | 100 (95.9 to 100) |
| Day 1: hSBA >=1:4 titer, Serogroup W | 95.5 (88.8 to 98.7) |
| Day 31: hSBA >=1:4 titer, Serogroup W | 100 (95.9 to 100) |
| Day 1: hSBA >=1:8 titer, Serogroup W | 85.2 (76.1 to 91.9) |
| Day 31: hSBA >=1:8 titer, Serogroup W | 100 (95.9 to 100) |
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:16 for participants with pre-vaccination hSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination hSBA titer \>= 1:8.
Results for this outcome have not been posted.
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:32 for participants with pre-vaccination rSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination rSBA titer \>= 1:8.
| percentage of participants | MenACYW: Group 1 |
|---|---|
| Day 1: rSBA >=1:8 titer, Serogroup A | 72.7 (62.2 to 81.7) |
| Day 31: rSBA >=1:8 titer, Serogroup A | 100 (95.9 to 100) |
| Day 1: rSBA >=1:128 titer, Serogroup A | 64.8 (53.9 to 74.7) |
| Day 31: rSBA >=1:128 titer, Serogroup A | 100 (95.9 to 100) |
| Day 1: rSBA >=1:8 titer, Serogroup C | 62.5 (51.5 to 72.6) |
| Day 31: rSBA >=1:8 titer, Serogroup C | 98.9 (93.8 to 100) |
| Day 1: rSBA >=1:128 titer, Serogroup C | 37.5 (27.4 to 48.5) |
| Day 31: rSBA >=1:128 titer, Serogroup C | 98.9 (93.8 to 100) |
| Day 1: rSBA >=1:8 titer, Serogroup Y | 63.5 (52.4 to 73.7) |
| Day 31: rSBA >=1:8 titer, Serogroup Y | 98.9 (93.8 to 100) |
| Day 1: rSBA >=1:128 titer, Serogroup Y | 56.5 (45.3 to 67.2) |
| Day 31: rSBA >=1:128 titer, Serogroup Y | 98.9 (93.8 to 100) |
| Day 1: rSBA >=1:8 titer, Serogroup W | 58.0 (47.0 to 68.4) |
| Day 31: rSBA >=1:8 titer, Serogroup W | 98.9 (93.8 to 100) |
| Day 1: rSBA >=1:128 titer, Serogroup W | 50.0 (39.1 to 60.9) |
| Day 31: rSBA >=1:128 titer, Serogroup W | 98.9 (93.8 to 100) |
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:32 for participants with pre-vaccination rSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination rSBA titer \>= 1:8.
Results for this outcome have not been posted.
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:16 for participants with pre-vaccination hSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination hSBA titer \>= 1:8.
| percentage of participants | MenACYW: Group 1 |
|---|---|
| Serogroup A | 93.2 (85.7 to 97.5) |
| Serogroup C | 97.7 (92.0 to 99.7) |
| Serogroup Y | 98.9 (93.8 to 100) |
| Serogroup W | 98.9 (93.8 to 100) |
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:16 for participants with pre-vaccination hSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination hSBA titer \>= 1:8.
Results for this outcome have not been posted.
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:32 for participants with pre-vaccination rSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination rSBA titer \>= 1:8.
| percentage of participants | MenACYW: Group 1 |
|---|---|
| Serogroup A | 89.8 (81.5 to 95.2) |
| Serogroup C | 96.6 (90.4 to 99.3) |
| Serogroup Y | 91.8 (83.8 to 96.6) |
| Serogroup W | 97.7 (92.0 to 99.7) |
Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:32 for participants with pre-vaccination rSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination rSBA titer \>= 1:8.
Results for this outcome have not been posted.
Anti-tetanus antibodies were measured by diphtheria, tetanus, pertussis multiplexed electrochemiluminescent (DTP-ECL) assay, a multiplexed serological assay that allowed for the simultaneous quantification of human antibodies to 6 specific antigens including diphtheria toxoid, tetanus toxoid, and 4 pertussis antigens: pertussis toxin, filamentous hemagglutinin, fimbriae and pertactin. The captured antibodies were then detected using a sulfotag-conjugated anti-human immunoglobulin (Ig)G conjugate.
| percentage of participants | MenACYW: Group 1 |
|---|---|
| Day 1: >= 0.01 IU/mL | 100 (95.9 to 100) |
| Day 31: >= 0.01 IU/mL | 100 (95.9 to 100) |
| Day 1: >= 0.1 IU/mL | 95.5 (88.8 to 98.7) |
| Day 31: >= 0.1 IU/mL | 100 (95.9 to 100) |
Anti-tetanus antibodies were measured by diphtheria, tetanus, pertussis multiplexed electrochemiluminescent (DTP-ECL) assay, a multiplexed serological assay that allowed for the simultaneous quantification of human antibodies to 6 specific antigens including diphtheria toxoid, tetanus toxoid, and 4 pertussis antigens: pertussis toxin, filamentous hemagglutinin, fimbriae and pertactin. The captured antibodies were then detected using a sulfotag-conjugated anti-human immunoglobulin (Ig)G conjugate.
Results for this outcome have not been posted.
Anti-tetanus antibodies were measured by DTP-ECL assay, a multiplexed serological assay that allowed for the simultaneous quantification of human antibodies to 6 specific antigens including diphtheria toxoid, tetanus toxoid, and 4 pertussis antigens: pertussis toxin, filamentous haemagglutinin, fimbriae and pertactin. The captured antibodies were then detected using a sulfotag-conjugated anti-human Ig G conjugate.
| IU/mL | MenACYW: Group 1 |
|---|---|
| Day 1 | 2.41 (1.77 to 3.30) |
| Day 31 | 13.7 (12.0 to 15.7) |
Anti-tetanus antibodies were measured by DTP-ECL assay, a multiplexed serological assay that allowed for the simultaneous quantification of human antibodies to 6 specific antigens including diphtheria toxoid, tetanus toxoid, and 4 pertussis antigens: pertussis toxin, filamentous haemagglutinin, fimbriae and pertactin. The captured antibodies were then detected using a sulfotag-conjugated anti-human Ig G conjugate.
Results for this outcome have not been posted.
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. An unsolicited AE is an observed AE that does not fulfill the conditions of solicited reactions (i.e.pre-listed in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination).
| Participants | MenACYW: Group 1 |
|---|---|
| Group 1: Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs) | 0 |
All noxious and unintended responses to a study vaccine related to any dose was considered adverse reactions (AR). A solicited reaction is an "expected" AR (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRB. An injection/administration site reaction is an AR at and around the injection/administration site. Injection/administration site reactions are commonly inflammatory reactions. They were considered to be related to the study vaccine administered. Systemic reactions were all ARs that were not injection or administration site reactions and included systemic manifestations such as headache, fever, as well as localized or topical manifestations that are not associated with the vaccination or administration site.
| Participants | MenACYW: Group 1 |
|---|---|
| Solicited injection site reactions | 67 |
| Solicited systemic reactions | 45 |
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. An unsolicited AE is an observed AE that does not fulfill the conditions of solicited reactions (i.e. pre-listed in the CRB in terms of diagnosis and/or onset window post-vaccination). Unsolicited AEs included both serious and non-serious unsolicited AEs.
| Participants | MenACYW: Group 1 |
|---|---|
| Group 1: Number of Participants With Unsolicited AEs | 28 |
A SAEs is defined as any untoward medical occurrence, at any dose that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, or other important medical event. An AESI (serious or non-serious) is defined as one of scientific and medical concern specific to the Sponsor's study vaccination or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate.
| Participants | MenACYW: Group 1 |
|---|---|
| SAE | 3 |
| AESI | 0 |
Collected over From the first study vaccine administration up to primary completion date of 09 March 2023, approximately 28 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MenACYW: Group 1 | 0/93 (0%) | 3/93 (3.2%) | 72/93 (77.4%) |
| MenACYW: Group 2 | — | — | — |
| Event | MenACYW: Group 1 | MenACYW: Group 2 |
|---|---|---|
| GastroenteritisInfections and infestations | 1/93 | — |
| GiardiasisInfections and infestations | 1/93 | — |
| Wrist FractureInjury, poisoning and procedural complications | 1/93 | — |
| Event | MenACYW: Group 1 | MenACYW: Group 2 |
|---|---|---|
| Injection Site PainGeneral disorders | 60/93 | — |
| Injection Site ErythemaGeneral disorders | 36/93 | — |
| MyalgiaMusculoskeletal and connective tissue disorders | 31/93 | — |
| Injection Site SwellingGeneral disorders | 28/93 | — |
| MalaiseGeneral disorders | 23/93 | — |
| HeadacheNervous system disorders | 20/93 | — |
| PyrexiaGeneral disorders | 14/93 | — |
Participants with data in Case report form (CRF) consisted of all study participants with CRF, i.e with data in the clinical database.
| Age, Continuous(year) | MenACYW: Group 1 | MenACYW: Group 2 | Total |
|---|---|---|---|
| Mean | 6.28 ± 0.578 | 6.26 ± 0.440 | 6.27 ± 0.505 |
| Sex: Female, Male(Participants) | MenACYW: Group 1 | MenACYW: Group 2 | Total |
|---|---|---|---|
| Female | 35 | 60 | 95 |
| Male | 58 | 56 | 114 |
| Race (NIH/OMB)(Participants) | MenACYW: Group 1 | MenACYW: Group 2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 93 | 113 | 206 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Aug 2022 to primary completion in Mar 2023, 6 months.
Results were first posted in May 2024, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanofi Pasteur, a Sanofi Company →